Abstract Neuromyelitis Optica (NMO) is a rare neuroinflammatory disorder with limited epidemiological data. Antibodies against aquaporin-4 (Aq4ab) are reported to be highly specific for NMO and NMO spectrum disorders (NMO-SD).
OBJECTIVE:To evaluate the efficacy, tolerability, optimal dosing, and monitoring of azathioprine in patients with neuromyelitis optica (NMO). METHODS: This was a chart review and telephone follow-up study of 99 patients with NMO spectrum of disorders (NMOSD) treated with azathioprine (1994-2009). NMOSD were NMO (2006 diagnostic criteria) or partial NMO forms (NMO-immunoglobulin G seropositive)
Background: Based on case series and anecdotal evidence, immunosuppression has been shown to reduce relapse rates and delay disability in Neuromyelitis Optica spectrum disorders (NMOSD) and is currently the mainstay of disease modifying treatment.
We report 12 aquaporin-4 antibody-positive patients Mayo Clinic patients identifiesince 2005) whose initial presenting symptom of neuromyelitis optica was intractable vomiting. The initialevaluation in 75% was gastroenterologic
Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory demyelinating disorder.
BACKGROUND: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years